

- **Name:**  
Takayuki Yoshino
  
- **Current Position:**  
Director, Department of Gastroenterology and Gastrointestinal Oncology  
National Cancer Center Hospital East
  
- **Country:** JAPAN
  
- **Educational Background:**  
1989-1995, National Defense Medical College  
1995-1997, Resident in National Defense Medical College Hospital  
1997-1999, Trainee in Division of Pathology, National Cancer Center Research Institute  
1999-2001, Trainee in Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East
  
- **Professional Experience:**  
1995-1997, Resident in National Defense Medical College Hospital  
1997-1999, Trainee in Division of Pathology, National Cancer Center Research Institute  
1999-2001, Trainee in Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East  
2001-2002, Staff physician in Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East  
2002-2007, Staff physician of Division of Gastrointestinal Oncology, Shizuoka Cancer Center  
2007- 2010, Staff physician in Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East  
2010- 2014 Chief, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East,  
2014- Present Director, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East
  
- **Professional Organizations:**  
America Society of Clinical Oncology, Active Member  
European Society for Medical Oncology, Active Member  
Japanese Society of Medical Oncology, Member  
Japanese Society of Clinical Oncology, Member  
Japanese Cancer Association, Member  
The Japanese Society of Internal Medicine, Member  
The Japanese Society of Gastroenterology, Member  
The Japanese Association for Molecular Target Therapy of Cancer, Member

• **Main Scientific Publications:**

1. Grothey A, **Yoshino T**, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. *N Engl J Med*. 2018 Mar 29;378(13):1177-1188.
2. Corcoran RB, **Yoshino T**, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients With BRAFV600E-Mutant Colorectal Cancer. *Cancer Discov*. 2018 Feb 5. pii: CD-17-1226.
3. **Yoshino T**, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. *Ann Oncol*. 2018 Jan 1;29(1):44-70.
4. van Geel RM, **Yoshino T**, et al. A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. *Cancer Discov*. 2017 Mar 31. pii: CD-16-0795.
5. Kuboki Y, **Yoshino T**. A multicenter phase 1/2 study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE). *Lancet Oncol*. 2017 Jul 28. pii: S1470-2045(17)30425-4.
6. Van Cutsem E, **Yoshino T**, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol*. 2016 Jul 5.
7. Mayer RJ, **Yoshino T**, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med*. 2015 May 14;372(20):1909-19.
8. Tabernero J, **Yoshino T**, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol*. 2015 May;16(5):499-508.
9. Grothey A, **Yoshino T**, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2013;381(9863):303-12.
10. **Yoshino T**, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. *Lancet Oncol*. 2012;13(10):993-1001.